DOCSLIB.ORG

COVID-19 in India: Disease Burden, Managing the Second Wave and Innovations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
COVID-19 in India: Disease Burden, Managing the Second Wave and Innovations CSD Working Paper Series: Towards a New Indian Model of Information and Communications Technology-Led Growth and Development COVID-19 in India: Disease Burden, Managing the second wave and Innovations ICT India Working Paper #54 Nirupam Bajpai and Manisha Wadhwa August 2021 CSD Working Paper Series - COVID-19 in India: Disease Burden, Managing the second wave and Innovations Table of Contents Executive Summary ....................................................................................................................................... 5 Introduction .................................................................................................................................................. 6 COVID-19 Vaccination Drive ....................................................................................................................... 10 Challenges related to COVID-19 vaccination Drive ................................................................................. 13 Gaps in Digital Platform ...................................................................................................................... 13 Shortage of Vaccine ............................................................................................................................ 13 Vaccine Wastage ................................................................................................................................. 13 Rural Challenge ................................................................................................................................... 13 Vaccine Hesitancy ............................................................................................................................... 14 Innovative approaches to address vaccine hesitancy ............................................................................. 14 Inter-departmental Coordination ............................................................................................................... 16 Health Initiatives ..................................................................................................................................... 17 e-Sanjeevani OPD ................................................................................................................................ 17 Infectious disease diagnostic lab (I-lab) .............................................................................................. 17 Robots ................................................................................................................................................. 17 Drones ................................................................................................................................................. 18 Remote monitoring systems ............................................................................................................... 18 AI-powered tools for screening .......................................................................................................... 18 Disinfectant Tunnel ............................................................................................................................. 18 COVI-SAFE Transportation System ...................................................................................................... 19 Phone Booth Testing ........................................................................................................................... 20 IoT-Based BIN-19 ................................................................................................................................. 21 UV SPOT .............................................................................................................................................. 22 Foot-operated hand sanitation device ............................................................................................... 22 Boat Clinics .......................................................................................................................................... 23 Bus Clinics ............................................................................................................................................ 24 Promoting use of Umbrellas for physical distancing .......................................................................... 24 Corona Shield ...................................................................................................................................... 24 Low Cost PPE Kits ................................................................................................................................ 24 Innovative sprayer for sanitization ..................................................................................................... 25 Medicab .............................................................................................................................................. 26 2 CSD Working Paper Series - COVID-19 in India: Disease Burden, Managing the second wave and Innovations Mobile Applications ............................................................................................................................ 27 Agricultural Solutions .............................................................................................................................. 28 Educational Initiatives ............................................................................................................................. 30 Initiatives by Department of Police ........................................................................................................ 32 AYURAKSHA......................................................................................................................................... 34 Initiatives by Indian Railways .................................................................................................................. 34 Other innovations ................................................................................................................................... 35 Women Self-Help Groups ................................................................................................................... 35 Floating supermarket .......................................................................................................................... 35 Frugal Innovations in Kerala ................................................................................................................ 36 Antiviral Fabric .................................................................................................................................... 40 AI-based Social Distancing Tracking Device ........................................................................................ 40 Rapid paper-strip test kit .................................................................................................................... 42 Negative pressure aerosol containment box: ..................................................................................... 42 Patient Coverall ................................................................................................................................... 42 M-19 Shields........................................................................................................................................ 43 Recommendations ...................................................................................................................................... 44 References .................................................................................................................................................. 46 Annexures ................................................................................................................................................... 53 Annexure 1: List of Comorbidities included under the vaccination programme ................................ 53 List of Tables Table 1: Mobile applications launched by various state governments ...................................................... 27 Table 2: Innovative Agricultural Interventions ........................................................................................... 28 Table 3: Educational Initiatives ................................................................................................................... 30 List of Figures Figure 1: Daily New Confirmed COVID-19 Cases .......................................................................................... 6 Figure 2: Second wave of COVID-19 is twice as severe as the first one ....................................................... 7 Figure 3: Decline in COVID-19 cases during second wave as steep as surge ................................................ 8 Figure 4: COVID-19 cases in India ................................................................................................................. 9 Figure 5: Rising test positivity rate in the districts of northeast ................................................................. 10 Figure 6: COVID-19 vaccination status as on July 15, 2021 ........................................................................ 12 Figure 7: Uneven distribution of Cold Chain Points .................................................................................... 14 Figure 8: Outreach Advocacy Campaign ..................................................................................................... 15 3 CSD Working Paper Series - COVID-19 in
Load more

Recommended publications
  • What Do We Know About India's Covaxin Vaccine?
    FEATURE Tamil Nadu, India COVID-19 VACCINES [email protected] BMJ: first published as 10.1136/bmj.n997 on 20 April 2021. Downloaded from Cite this as: BMJ 2021;373:n997 http://dx.doi.org/10.1136/bmj.n997 What do we know about India’s Covaxin vaccine? Published: 20 April 2021 India has rapidly approved and rolled out Covaxin, its own covid-19 vaccine. Kamala Thiagarajan examines what we know so far. Kamala Thiagarajan freelance journalist Who developed Covaxin? cheapest purchased by any country in the world at 206 rupees per shot for the 5.5 million doses the Covaxin was developed by Indian pharmaceutical government currently has on order. The government company Bharat Biotech in collaboration with the has capped the price of the vaccine sold in the private Indian Council of Medical Research, a government market, with private hospitals able to charge up to funded biomedical research institute, and its 250 rupees.13 subsidiary the National Institute of Virology. Covaxin does not require storage at sub-zero Bharat Biotech has brought to market 16 original temperatures, which would be hard to maintain in vaccines, including for rotavirus, hepatitis B, Zika India’s climate and with the frequent power cuts in virus, and chikungunya.1 The company reportedly rural areas. Covaxin is available in multi-dose vials spent $60-$70m (£43-£50m; €50-€58m) developing and is stable at the 2-8°C that ordinary refrigeration Covaxin.2 can achieve. How does Covaxin work? Bharat Biotech says it has a stockpile of 20 million The vaccine is similar to CoronaVac (the Chinese doses of Covaxin for India and is in the process of vaccine developed by Sinovac)3 in that it uses a manufacturing 700 million doses at its four facilities complete infective SARS-CoV-2 viral particle in two cities by the end of the year.
    [Show full text]
  • 0 January to July 2021
    0 www.journalsofindia.com January to July 2021 SCIENCE & TECH ............................................................................................................................................................... 6 1. REUSABLE LAUNCH VEHICLE TECHNOLOGY DEMONSTRATION PROGRAMME(RLV-TD) ................................................. 6 2. GAGANYAAN MISSION ..................................................................................................................................................... 6 3. MARS ORBITER MISSION (MOM) ..................................................................................................................................... 6 4. CHANDRAYAAN MISSION................................................................................................................................................. 7 5. SOLAR MISSION ............................................................................................................................................................... 8 6. ARTEMIS ACCORD ............................................................................................................................................................ 9 7. NATIONAL MISSION ON INTERDISCIPLINARY CYBER-PHYSICAL SYSTEM (NMICPS) ....................................................... 10 8. SMART ANTI-AIRFIELD WEAPON (SAAW) ...................................................................................................................... 10 9. AQUAPONICS ................................................................................................................................................................
    [Show full text]
  • Bcpct]Ttsbc^Prc U^A Dq[XRV^^S
    6 < %()(=#%% 53%7==,>3='$()6(=#%% (#-'>3='$()6(=#%% $'()"*$+&,- %( !"# $$%& 2(*3-% (566)(37)% 3 0 4 $5 3 $1 2 0 .8 9 8 ++0 0 .:; . !" . / 01 $ %'( $) '# *' it for the last eight to nine notable achievements to its months, “where is the UN in name in the 75 years of its aking a strong case for a this joint fight. Where is the experience, including the pre- Msignificant role for India effective response.” vention of a third world war, in the United Nations, Prime Focussing on a more “we can’t deny terrorist attacks 0 Minister Narendra Modi on prominent role for India in the shook the world”. Saturday stressed the need for UN and fight against corona, “We have successfully ne of the oldest partners changes in the international the Prime Minister avoided avoided a third world war but Oof the BJP — the body and questioned its posi- making any reference to ongo- we cannot deny many wars Shiromani Akali Dal — which tion in fighting the coron- ing tension at the Line of happened, many civil wars has been with it through thick avirus pandemic. Actual Control (LAC) and happened. Terrorist attack and thin for decades, finally He also assured the global frosty ties with Pakistan in his shook the world. Blood was quit the National Democratic Q community that India will pro- 20-minute speech. He also did spilled. Those were killed were Alliance (NDA) on Saturday, vide corona vaccine to the not respond to Pakistan Prime like you and me. Children left signaling a complete political world as it is the world’s biggest Minister Imran Khan’s remarks the world prematurely,” he said.
    [Show full text]
  • News in Focus ISHANT CHAUHAN/AP/SHUTTERSTOCK ISHANT People Queue to Refill Oxygen Cylinders for Overwhelmed Medical Facilities in New Delhi
    The world this week News in focus ISHANT CHAUHAN/AP/SHUTTERSTOCK ISHANT People queue to refill oxygen cylinders for overwhelmed medical facilities in New Delhi. CORONAVIRUS VARIANTS ARE SPREADING IN INDIA — WHAT SCIENTISTS KNOW SO FAR Variants including B.1.617 have been linked to India’s surge in infections. Researchers are hurrying to determine how much of a threat they pose. By Gayathri Vaidyanathan detected in India might be more transmissible variants were behind a series of surges in India. and slightly better at evading immunity than Genomic data indicated that B.1.1.7, first iden- cientists are working to understand existing variants. Animal models also hint that tified in the United Kingdom, was dominant in several coronavirus variants now it might be able to cause more severe disease. Delhi and the state of Punjab, and a new variant circulating in India, where a ferocious Researchers want to know whether this variant dubbed B.1.618 was present in West Bengal. second wave of COVID-19 has devas- and others might be driving the second wave B.1.617 was dominant in Maharashtra. tated the nation and caught authori- and what kind of danger they pose globally. But, since then, B.1.617 has overtaken B.1.618 Sties unawares. The country recorded nearly In just a few weeks, the B.1.617 variant has in West Bengal, has become the leading vari- 400,000 new infections on 9 May, taking its become the dominant strain across India and ant in many states, and is increasing rapidly total to more than 22 million (see ‘Surging has spread to about 40 nations, including the in Delhi.
    [Show full text]
  • COVID-19 Vaccines Update Supplement Week Of: 5Th April, 2021
    CARPHA UPDATE FOR Incident Manager / SITUATION REPORT COVID-19 Vaccines Update Supplement Week of: 5th April, 2021 I. Overview of Development and Regulatory Approvals: • 85 candidate vaccines are in clinical development: 16 in Phase 3 trials, and 4 in Phase 4 trials – see Figure in CARPHA COVID-19 Vaccine Regulatory Tracker (Phases tab). • 13 vaccines have received regulatory approvals in various countries, and 16 vaccines are at various stages of engagement with WHO for emergency use listing (EUL). • 4 vaccines have been approved by WHO for Emergency Use Listing: Pfizer-BioNTech’s vaccine: COMIRNATY®, AstraZeneca-SK Bio, AstraZeneca-SII (Covishield), and Janssen-Cilag. • 4 additional vaccines are expected to be approved by WHO in April – Tables 1 and 3. • There are 3 additional vaccines being considered by WHO but these are at the stage of submitting expressions of interest: Bharat Biotech, Clover Biopharmaceuticals-GSK + Dynavax, and BioCubaFarma (Cuba). • The WHO Strategic Advisory Group of Experts on Immunization (SAGE) interim recommendations and background documents are available for vaccines by: Moderna, Pfizer-BioNTech, AstraZeneca-Oxford and Janssen-Cilag at SAGE Interim Guidance. The recommendations provide guidance on the use the vaccines, including use in various groups. • Reports of rare clotting events among vaccinees continue to be assessed by various regulators. The EU's European Medicines Agency (EMA) has stated that there was no evidence to support decisions by regulators to restrict the use of Oxford-AstraZeneca vaccines in some age groups. The WHO maintains that the benefit-risk balance of the vaccine remains favorable. • CARPHA has shared its COVID-19 vaccine regulatory tracker with Member States for viewing as updates are made.
    [Show full text]
  • V.3 1/25/2021 COVID-19 Vaccine FAQ Sheet
    COVID-19 Vaccine FAQ Sheet (updated 1/25/2021) The AST has received queries from transplant professionals and the community regarding the COVID-19 vaccine. The following FAQ was developed to relay information on the current state of knowledge. This document is subject to change and will be updated frequently as new information or data becomes available. What kinds of vaccines are available or under development to prevent COVID-19? There are currently several vaccine candidates in use or under development. In the United States, the Government is supporting six separate vaccine candidates. Several other vaccines are also undergoing development outside of the United States government sponsorship and further information can be found here: • NYTimes Coronavirus Vaccine Tracker: https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine- tracker.html • Washington Post Vaccine Tracker: https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update- coronavirus/ The types of vaccines are as follows (January 25, 2021) 1: Table 1: Vaccines Under Development Vaccine Type Compound Name Clinical Trial Notes [Sponsor] Phase mRNA mRNA-1273 Phase 3 Emergency use in [Moderna] U.S., E.U., other countries Approved in Canada BNT162b2 [Pfizer] Phase 2/3 Emergency use in U.S., E.U., other countries Also approved in Canada and other countries Replication- AZD1222 Phase 2/3 Emergency use in defective [AstraZeneca] Britain, India, other adenoviral vector countries (not U.S.) Ad26.COV2.S Phase 3 [Janssen] v.3 1/25/2021 Recombinant- NVX-CoV2373 Phase 3 subunit-adjuvanted [Novavax] protein Recombinant SARS- Phase 1/2 CoV-2 Protein Antigen + AS03 Adjuvant [Sanofi Pasteur/GSK] Inactivated CoVaxin [Bharat Phase 3 Emergency Use in coronavirus Biotech] India BBIBP-CorV Phase 3 Approved China, [Sinopharm] Bahrain, UAE; Emergency use elsewhere (not U.S.) Both of the mRNA SARS-CoV-2 vaccines (Moderna, Pfizer) have been approved by Emergency Use Authorization by the U.S.
    [Show full text]
  • Overview of Aarogya Setu Application Shweta Devidas Kedare1
    International Research Journal of Engineering and Technology (IRJET) e-ISSN: 2395-0056 Volume: 07 Issue: 06 | June 2020 www.irjet.net p-ISSN: 2395-0072 Overview of Aarogya Setu Application Shweta Devidas Kedare1 1Shweta Devidas Kedare, Department of Master of Computer Application, ASM IMCOST, Maharashtra, India ---------------------------------------------------------------------***--------------------------------------------------------------------- Abstract - The app - Aarogya Setu, which means "bridge to health" in Sanskrit -It is an Indian app which was launched on April 2nd 2020, by Indian government. It is designed as a Coronavirus, or COVID-19 contact tracing app that uses the Bluetooth and location technology in phones to note when you are near another user who also uses the Aarogya Setu app. In case someone you have come in close proximity to is confirmed infected, you are alerted. The app alerts are produced by instructions on how to self-isolate and what to do in case you develop symptoms. Basically this app gives basic information about Covid-19, including hygiene and social distancing protocols. It also has details of how one could donate to the prime minister’s coronavirus-specific relief fund, PM-Cares. India has made it mandatory for government and private sector employees to download it But users and experts in India and around the world say the app raises huge data security concerns. KeyWords: security, data, private, information, COVID-19, technology, location, bluetooth, proximity, etc. 1. INTRODUCTION Since the risk of COVID-19 started increasing in India so, The government of India decided to launch the application, name Aarogya Setu, which was intended to monitor the ratio of COVID-19 patients in India .This app is an updated version of an earlier app called Corona Kavach (now discontinued) which was released earlier by the Government of India.
    [Show full text]
  • Immunogenic Potential of DNA Vaccine Candidate, Zycov-D Against SARS-Cov-2 in Animal Models
    Vaccine 39 (2021) 4108–4116 Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Immunogenic potential of DNA vaccine candidate, ZyCoV-D against SARS-CoV-2 in animal models Ayan Dey a, T.M. Chozhavel Rajanathan a, Harish Chandra a, Hari P.R. Pericherla a, Sanjeev Kumar b, Huzaifa S. Choonia a, Mayank Bajpai a, Arun K. Singh b, Anuradha Sinha a, Gurwinder Saini a, Parth Dalal a, Sarosh Vandriwala a, Mohammed A. Raheem a, Rupesh D. Divate a, Neelam L. Navlani a, Vibhuti Sharma b, ⇑ Aashini Parikh b, Siva Prasath a, M. Sankar Rao a, Kapil Maithal a, a Vaccine Technology Centre, Cadila Healthcare Ltd, Ahmedabad, India b Zydus Research Centre, Cadila Healthcare Ltd, Ahmedabad, India article info abstract Article history: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), initially originated in China in year Received 15 February 2021 2019 and spread rapidly across the globe within 5 months, causing over 96 million cases of infection Received in revised form 21 May 2021 and over 2 million deaths. Huge efforts were undertaken to bring the COVID-19 vaccines in clinical devel- Accepted 28 May 2021 opment, so that it can be made available at the earliest, if found to be efficacious in the trials. We devel- Available online 1 June 2021 oped a candidate vaccine ZyCoV-D comprising of a DNA plasmid vector carrying the gene encoding the spike protein (S) of the SARS-CoV-2 virus. The S protein of the virus includes the receptor binding domain Keywords: (RBD), responsible for binding to the human angiotensin converting enzyme (ACE-2) receptor.
    [Show full text]
  • A Review of India's Contact-Tracing App, Aarogya Setu
    Doc Title A Review of India’s Contact-Tracing App, Aarogya Setu A - Front Page two line title ARTICLE A Review of India’s Contact-tracing App, Aarogya Setu The Government of India’s Ministry of Electronics and Information Technology (MeitY) agency launched Aarogya Setu, a contact-tracing mobile application. Aarogya Setu has been created by the National Informatic Centre (NIC) in response to the COVID-19 crisis, as a way to collect and understand public health-related data.1 The application uses mobile phones to perform a cross reference of individuals’ data with the database held by Indian Council of Medical Research (ICMR), “On various online discussion which was specially created as part of ongoing COVID-19 testing infrastructure. forums, there is significant The purpose of Aarogya Setu is to notify users whether they have been exposed interest in the workings of this to COVID-19, by checking their proximity to known patients. In the event of a government- managed app match, the application will warn other users in the area that an infected person and its use of personal and is in their proximity. According to the press release dated May 26, 2020 available sensitive user data..”123 on mygov.in website, roughly 114 million users have adopted the app.2 Aarogya Setu also collects some sensitive personal information including gender and recent travel information. This has raised privacy and security questions. This whitepaper evaluates the functionality and data privacy aspects of the application. About Aarogya Setu Aarogya Setu app is a self-assessment disease monitoring app launched by the Indian government.
    [Show full text]
  • Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St
    Bharat Biotech Inks Licensing Deal with Washington University School of Medicine in St. Louis to advance COVID-19 Intranasal Vaccine Technology Hyderabad, India, 23 September 2020: Vaccine Innovator, Bharat Biotech announces today, a licensing agreement with Washington University School of Medicine in St. Louis for a novel chimp- adenovirus, single dose intranasal vaccine for COVID-19. Bharat Biotech owns the rights to distribute the vaccine in all markets except USA, Japan and Europe. While the Phase I trials will take place in Saint Louis University’s Vaccine & Treatment Evaluation Unit, Bharat Biotech, upon obtaining the required regulatory approval, will pursue further stages of clinical trials in India and undertake large scale manufacture of the vaccine at its GMP facility located in Genome Valley, Hyderabad. We are proud to collaborate on this innovative vaccine. We envision that we will scale this vaccine to 1 billion doses, translating to 1 billion individuals vaccinated receiving a single-dose regimen. An intranasal vaccine will not only be simple to administer but reduce the use of medical consumables such as needles, syringes, etc., significantly impacting the overall cost of a vaccination drive. Our experience in viral vaccines, manufacturing capabilities, and distribution continue to be our strong suit in ensuring safe, efficacious, and affordable vaccines. It is prudent for Bharat to be involved in diverse but tenable projects to provide a much-needed vaccine against COVID-19 reaches all citizens of the world.” Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, stated. This intranasal vaccine candidate has shown unprecedented levels of protection in mice studies; the technology and data having been recently published in the prestigious scientific journal Cell and in an editorial in Nature.
    [Show full text]
  • Determinants of Childhood Immunisation Coverage in Urban Poor Settlements of Delhi, India: a Cross-Sectional Study
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2016-013015 on 26 August 2016. Downloaded from Determinants of childhood immunisation coverage in urban poor settlements of Delhi, India: a cross-sectional study Niveditha Devasenapathy,1 Suparna Ghosh Jerath,1 Saket Sharma,1 Elizabeth Allen,2 Anuraj H Shankar,3 Sanjay Zodpey1 To cite: Devasenapathy N, ABSTRACT Strengths and limitations of this study Ghosh Jerath S, Sharma S, Objectives: Aggregate data on childhood et al. Determinants of immunisation from urban settings may not reflect the ▪ childhood immunisation We report current estimates of childhood com- coverage among the urban poor. This study provides coverage in urban plete immunisation including hepatitis B vaccine poor settlements of Delhi, information on complete childhood immunisation coverage from representative urban poor com- India: a cross-sectional study. coverage among the urban poor, and explores its munities in the Southeast of Delhi. BMJ Open 2016;6:e013015. household and neighbourhood-level determinants. ▪ The sample size was large and therefore our doi:10.1136/bmjopen-2016- Setting: Urban poor community in the Southeast effect estimates for coverage and determinants 013015 district of Delhi, India. were precise. Participants: We randomly sampled 1849 children ▪ We quantify unknown neighbourhood effects on ▸ Prepublication history and aged 1–3.5 years from 13 451 households in 39 this outcome using median ORs which are more additional material is clusters (cluster defined as area covered by a intuitively understood. available. To view please visit community health worker) in 2 large urban poor ▪ Based on the data, representative of only one the journal (http://dx.doi.org/ settlements.
    [Show full text]
  • Asia COVID-19 & Vaccine Tracker
    9 July 2021 Free to View Asia COVID-19 & Vaccine Tracker Economics - Asia Tougher restrictions As COVID-19 cases continue to surge across Asia, more Yun Liu authorities have re-imposed restrictions or even lockdowns Economist The Hongkong and Shanghai Banking Corporation Limited But this has increased the urgency to ramp up vaccine Frederic Neumann procurement and roll-out in the region Co-Head of Asian Economics Research The Hongkong and Shanghai Banking Corporation Limited Some economies have started pilot programmes to revive tourism, but a full re-opening may take a long time Maitreyi Das Associate Bangalore Déjà vu No end in sight just yet. The Delta variant is causing daily new COVID-19 cases to surge to new record highs across Asia, prompting more governments to re-impose tougher restrictions. This is particularly evident in ASEAN, where cases in Indonesia and Vietnam have been rising sharply. The former has extended its tightening measures throughout the country until 20 July, while the latter will impose a strict lockdown in Ho Chi Minh City (HCMC) from 9 July for 15 days. Meanwhile, just two weeks before the Tokyo Olympics, Japan is set to declare its fourth state of emergency in Tokyo from 12 July to 20 August, raising the possibility of no spectators attending the games. Meanwhile, Singapore is the only country that has decided to ease its social restrictions from 12 July, as new cases remain low. Urgency on vaccination The recent outbreaks in the region has alerted the authorities that the key to exiting the pandemic is to accelerate vaccine procurement and roll-out.
    [Show full text]